The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO


Emily Leproust, CEO and Co-founder, Twist Bioscience

Bio and Contact Info

Chapters:

0:00 We found a big market with unhappy customers

6:05 Inkjet printing oligos on silicon

11:21 Why you?

14:32 Of what applications for DNA should the average person be most aware?

22:35 Some of these consumer products for sale now

31:18 The future of DNA synthesis

In 2013 Twist Bioscience was a newcomer to a market that most of us thought was saturated, cornered, commoditized—that of synthetic DNA. But Emily Leproust and her co-founders saw something different. They saw "a big market with unhappy customers.” Today, with a radically disruptive technology, they are market dominant. Twist is a publicly traded company whose stock has doubled already once since they IPOd last year. Imagine, a DNA synthesis company going public! And then seeing their stock perform so well. This is tricky for the most hyped of tech or biotech startups.

And the demand for DNA is only going up, and dramatically up. When Twist signed a deal with Gingko Bioworks in 2017 for 1 billion bases, that single order was bigger than the entire market two years previous.

Today, for the first time the Twist CEO joins us on the program to talk about where her company came from (another planet?!) and about why there is such demand for DNA. What applications should we know most about? Is all this demand the result of hyped up investment, or are the products going to market?

“Synthetic biology is currently changing our lives and people don’t even realize it. People won’t say, 'oh that’s cool synthetic biology.' They won’t. They’ll just know they have a leather jacket. And there’s no cows harmed in the making of that leather jacket because that leather jacket was created from kampuchea and synthetic biology. And I think that’s the future of the impact of our industry.”



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup